Substance / Medication

Dihydroergocryptine

Overview

Active Ingredient
dihydroergocryptine
RxNorm CUI
3417

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
[Effect of alpha dihydroergocryptine in patients with fibrocystic breast disease].
Castillo Eugenio, Garibay Miguel, Mirabent Felio · Ginecol Obstet Mex · 2006
PMID: 17357577RCT
Bioequivalence of a novel high-dose oral formulation of alpha-dihydroergocryptine.
de Mey Christian, Stamenova Paraskeva, Daskalov Marin et al. · Arzneimittelforschung · 2006
PMID: 16618013RCT
Alpha-dihydroergocryptine in the long-term therapy of Parkinson's disease.
Mailland Enrico, Magnani Paola, Ottillinger Bertram · Arzneimittelforschung · 2004
PMID: 15553103Trial
Single dose pharmacokinetics of alpha-dihydroergocryptine in patients with moderate to severe renal insufficiency.
de Mey Christian, Sułowicz Władyslaw, Stompór Tomasz et al. · Arzneimittelforschung · 2003
PMID: 14677372Trial
Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans.
de Mey C, Althaus M, Ezan E et al. · Clin Pharmacol Ther · 2001
PMID: 11503008Trial
Alpha-dihydroergocryptine and predictive factors in migraine prophylaxis.
Micieli G, Cavallini A, Marcheselli S et al. · Int J Clin Pharmacol Ther · 2001
PMID: 11332869Trial
Study on the interaction of the dopamine agonist alpha-dihydroergocryptine with the pharmacokinetics of digoxin.
Retzow A, Althaus M, de Mey C et al. · Arzneimittelforschung · 2000
PMID: 10965414Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Dihydroergocryptine (substance)
SNOMED CT
412173004
UMLS CUI
C0012290
RxNorm CUI
3417

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.